US5516528A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dietary phytoestrogen in estrogen replacement therapy
Assignee: Solae LLC
•
Filing: 1995-01-13
•
Granted: 1996-05-14
•
Expires: 2015-01-13
Abstract
Abstract Disclosed is a pharmaceutical composition for oral delivery. The composition includes about 1-2 mg mammalian estrogen and about 25-100 mg phytoestrogen. Compositions of the type described above are utilized, for example, in a therapeutic regimen designed to reduce the risk of coronary heart disease and osteoporosis in postmenopausal women. This method comprises the oral administration of a composition comprising a mixture of estrogen and phytoestrogen, the dosages of mammalian estrogen and phytoestrogen being about 1-2 mg, about 25-100 mg, respectively.
Inventors
- 👤 Claude L. Hughes
- 👤 Edna C. Henley
- 👤 Thomas B. Clarkson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
31 words
A pharmaceutical composition for oral delivery comprising a combination of mammalian estrogen and soy-derived phytoestrogen in an amount sufficient to reduce the risk of coronary heart disease and osteoporosis in women.
Claim 2
Dependent Claim
31 words
A pharmaceutical composition for oral delivery comprising a combination of mammalian estrogen and soy-derived phytoestrogen in an amount sufficient to reduce the risk of coronary heart disease and osteoporosis in women.
Claim 3
Dependent Claim
35 words
The pharmaceutical composition of claim 1, wherein the amount sufficient to reduce the risk of coronary heart disease and osteoporosis in women is about 1-2 mg of mammalian estrogen combined with about 25-100 mg phytoestrogen.
Claim 4
Dependent Claim
13 words
A pharmaceutical composition of claim 1 which is in pill or capsule form.
Claim 5
Dependent Claim
13 words
A pharmaceutical composition of claim 1 wherein the soy-derived mammalian estrogen is estradiol.
Claim 6
Dependent Claim
12 words
A pharmaceutical composition of claim 1 wherein the phytoestrogen is an isoflavone.
Claim 7
Dependent Claim
11 words
A pharmaceutical composition of claim 5 wherein the isoflavone is genistein.
Claim 8
Dependent Claim
11 words
A pharmaceutical composition of claim 5 wherein the isoflavone is daidzein.
Claim 9
Independent Claim
32 words
A method for reducing the risk of coronary heart disease and osteoporosis in women, the method comprising administering orally a combination of mammalian estrogen and soy-derived phytoestrogen in a therapeutically effective amount.
Claim 10
Independent Claim
32 words
A method for reducing the risk of coronary heart disease and osteoporosis in women, the method comprising administering orally a combination of mammalian estrogen and soy-derived phytoestrogen in a therapeutically effective amount.
Claim 11
Dependent Claim
28 words
The method of claim 8 wherein the therapeutically effective amount is a daily dosage of mammalian estrogen of about 1-2 mg, and soy-derived phytoestrogen of about 25-100 mg.
Claim 12
Dependent Claim
11 words
A method of claim 8 wherein the mammalian estrogen is estradiol.
Claim 13
Dependent Claim
12 words
A method of claim 8 wherein the soy-derived phytoestrogen is an isoflavone.
Claim 14
Dependent Claim
10 words
A method of claim 11 wherein the isoflavone is genistein.
Claim 15
Dependent Claim
10 words
A method of claim 11 wherein the isoflavone is daidzein.
Claim 16
Dependent Claim
23 words
An estrogen replacement therapy regimen, comprising the oral coadministration of a combination of mammalian estrogen and soy-derived phytoestrogen in a therapeutically effective amount.
Claim 17
Dependent Claim
23 words
An estrogen replacement therapy regimen, comprising the oral coadministration of a combination of mammalian estrogen and soy-derived phytoestrogen in a therapeutically effective amount.
Claim 18
Dependent Claim
31 words
The estrogen replacement therapy regimen of claim 14 wherein the therapeutically effective amount is a daily dosage of mammalian estrogen of about 1-2 mg, and soy-derived phytoestrogen of about 25-100 mg.
Claim 19
Dependent Claim
11 words
A method of claim 14 wherein the mammalian estrogen is estradiol.
Claim 20
Dependent Claim
12 words
A method of claim 14 wherein the soy-derived phytoestrogen is an isoflavone.
Claim 21
Dependent Claim
10 words
A method of claim 17 wherein the isoflavone is genistein.
Claim 22
Dependent Claim
10 words
A method of claim 17 wherein the isoflavone is daidzein.
References Cited (Backward Citations)
US5277910A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-05-14 | 1999-11-13 | 2000-05-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-05-14 | 2003-11-13 | 2004-05-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-05-14 | 2007-11-13 | 2008-05-14 | $7700.00 | Window Closed / Lapsed |